BAX logo

Baxter International Inc. Stock Price

NYSE:BAX Community·US$9.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author

BAX Share Price Performance

US$18.31
-14.90 (-44.87%)
US$24.07
Fair Value
US$18.31
-14.90 (-44.87%)
23.9% undervalued intrinsic discount
US$24.07
Fair Value
Price US$18.31
AnalystConsensusTarget US$24.07
AnalystHighTarget US$47.00
AnalystLowTarget US$21.54

BAX Community Narratives

AnalystConsensusTarget·
Fair Value US$24.07 23.9% undervalued intrinsic discount

BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AnalystHighTarget·
Fair Value US$43.95 58.3% undervalued intrinsic discount

Aging Populations And Rising Chronic Disease Will Expand Care Access

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value US$19 3.6% undervalued intrinsic discount

Global Healthcare Spending And Aging Will Squeeze Hospital Revenues

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Updated Narratives

BAX logo

BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026

Fair Value: US$24.07 23.9% undervalued intrinsic discount
16 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BAX logo

Global Healthcare Spending And Aging Will Squeeze Hospital Revenues

Fair Value: US$19 3.6% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BAX logo

Aging Populations And Rising Chronic Disease Will Expand Care Access

Fair Value: US$43.95 58.3% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards

Baxter International Inc. Key Details

US$11.0b

Revenue

US$6.8b

Cost of Revenue

US$4.2b

Gross Profit

US$4.5b

Other Expenses

-US$355.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.69
37.93%
-3.22%
131.7%
View Full Analysis

About BAX

Founded
1931
Employees
38000
CEO
Andrew Hider
WebsiteView website
www.baxter.com

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Recent BAX News & Updates

Recent updates

No updates